Title: A double-blind controlled evaluation of the sebosuppressive activity of topical erythromycin-zinc complex.

Title Abreviation: Eur J Clin

Pharmacol Date of Pub: 1995

Author: PiĶerard-Franchimont C; Goffin V; Visser JN; Jacoby H;

PiĶerard GE;

Issue/Part/Supplement: 1-2 Volume Pagination: 57-60

Issue: 49

MESH Headings: Acetic Acids*; Acne Vulgaris*; Administration, Topical*; Adult*; Antibiotics, Macrolide*; Double-Blind Method*; Drug Therapy, Combination*; Erythromycin*; Human; Male; Sebum*; -PG-;

Journal Title Code: EN4 Publication Type: CLINICAL TRIAL

Date of Entry: 960923N Entry Month: 9611

Country: GERMANY Index Priority: 2

Language: Eng Unique Identifier: 96287397

Unique Identifier:

96287397 ISSN: 0031-6970


Abstract: In a double-blind randomised study, 14 volunteers applied 4% erythromycin plus 1.2% zinc (Zineryt lotion) and 4% erythromycin lotions, each on half of the forehead twice daily for 3 months. The sebum output was evaluated at 3-week intervals using the photometric and the lipid-sensitive film methods. Evaluations of casual level (CL) and sebum excretion rate (SER) were made with a Sebumeter, and total area of lipid spots (TAS) was measured on Sebutapes. Compared to baseline values, the formulation of the erythromycin-zinc complex induced significant reductions in SER after 6 and 9 weeks, and in CL and TAS at 3, 6, 9 and 12 weeks. The mean reduction in TAS was over 20% for four successive 1-h samplings on completion of the study. Significant reductions in CL, SER and TAS were observed for the erythromycin-zinc formulation compared to the control lotion at 6 and 9 weeks, and also at 3 weeks for SER and TAS, and at 12 weeks for CL and TAS. This study indicates that sebum output is significantly reduced by the erythromycin-zinc complex. This reduction is theoretically beneficial for the acneic patient. Abstract By: Author

Address: Department of Dermatopathology, University of LiĶege, Belgium.

Torna a zinco